Therefore, further exploration of the mechanisms underlying CDK6 overexpression and the development of combination strategies to downregulate CDK6 expression have significant clinical value for overcoming CDK4/6i resistance in hormone-independent cancers, such as lung cancer. Here, CDK6 is linked to lung cancer.